Long-term response to sunitinib therapy for metastatic renal cell carcinoma

Clinical Genitourinary Cancer

Volumn 11, Issue 3, 2013, Pages 297-302

  Molina, Ana M ^a,b   Jia, Xiaoyu ^a   Feldman, Darren R ^a,b   Hsieh, James J ^a,b   Ginsberg, Michelle S ^a   Velasco, Susanne ^a   Patil, Sujata ^a   Motzer, Robert J ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Metastatic; Renal cell carcinoma; Sunitinib; Systemic therapy; Targeted therapy

Indexed keywords

SUNITINIB;

ADULT; AGED; ANEMIA; ARTICLE; BLEEDING; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER PATIENT; DIARRHEA; DRUG ERUPTION; DRUG FEVER; FATIGUE; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HIGH RISK POPULATION; HUMAN; HYPERTENSION; HYPOPHOSPHATEMIA; KIDNEY METASTASIS; LUNG METASTASIS; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RETROSPECTIVE STUDY; RISK FACTOR; SIDE EFFECT; TREATMENT RESPONSE; VOMITING;

METASTATIC; RENAL CELL CARCINOMA; SUNITINIB; SYSTEMIC THERAPY; TARGETED THERAPY;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; BONE NEOPLASMS; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PYRROLES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84883445852     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2013.04.001     Document Type: Article

References (29)

1. R.J. Motzer, T.E. Hutson, P. Tomczak Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 2007 115 124
2. R.J. Motzer, T.E. Hutson, P. Tomczak Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma J Clin Oncol 27 2009 3584 3590
3. R.J. Motzer, B. Escudier, S. Oudard Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 2008 449 456
4. G. Hudes, M. Carducci, P. Tomczak Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 2007 2271 2281
5. B.I. Rini, S. Halabi, J.E. Rosenberg Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206 J Clin Oncol 26 2008 5422 5428
6. B. Escudier, A. Pluzanska, P. Koralewski Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial Lancet 370 2007 2103 2111
7. C.N. Sternberg, I.D. Davis, J. Mardiak Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial J Clin Oncol 28 2010 1061 1068
8. R.J. Motzer, M.D. Michaelson, B.G. Redman Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma J Clin Oncol 24 2006 16 24
9. R.J. Motzer, B.I. Rini, R.M. Bukowski Sunitinib in patients with metastatic renal cell carcinoma JAMA 295 2006 2516 2524
10. A.M. Molina, D.R. Feldman, M.H. Voss Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma Cancer 118 2012 1868 1876
11. R.J. Motzer, T.E. Hutson, M.R. Olsen Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma J Clin Oncol 30 2012 1371 1377
12. R.J. Motzer, G.R. Hudes, M.S. Ginsberg Phase I/II trial of sunitinib plus gefitinib in patients with metastatic renal cell carcinoma Am J Clin Oncol 33 2010 614 618
13. D.R. Feldman, M.S. Baum, M.S. Ginsberg Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma J Clin Oncol 27 2009 1432 1439
14. M.E. Gore, C. Szczylik, C. Porta Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial Lancet Oncol 10 2009 757 763
15. E.L. Kaplan, P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
16. J.R. Anderson, K.C. Cain, R.D. Gelber Analysis of survival by tumor response J Clin Oncol 1 1983 710 719
17. U. Dafni Landmark analysis at the 25-year landmark point Circ Cardiovasc Qual Outcomes 4 2011 363 371
18. R.H. Motzer, T. E, J. Reeves et al. Randomized, open Label, phase III trial of Pazopanib versus sunitinib in first-line treatment of patients with metastatic renal cell carcinoma (mRCC): results of the COMPARZ trial Ann Oncol 23 suppl 9 2012 (abstract LBA8-PR)
19. R.J. Motzer, M. Mazumdar, J. Bacik Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma J Clin Oncol 17 1999 2530 2540
20. R.J. Motzer, M.D. Michaelson, J. Rosenberg Sunitinib efficacy against advanced renal cell carcinoma J Urol 178 2007 1883 1887
21. C. Porta, C. Szczylik, S. Bracarda Short- and long-term safety with sunitinib in an expanded access trial in metastatic renal cell carcinoma (mRCC) J Clin Oncol 26 suppl 2008 (abstract 5114)
22. D.Y. Heng, B.I. Rini, J. Garcia Prolonged complete responses and near-complete responses to sunitinib in metastatic renal cell carcinoma Clin Genitourin Cancer 5 2007 446 451
23. L. Albiges, S. Oudard, S. Negrier Complete remission with tyrosine kinase inhibitors in renal cell carcinoma J Clin Oncol 30 2012 482 487
24. J. Ayllon, B. Beuselinck, A. Morel Long-term response and postsurgical complete remissions after treatment with sunitinib malate, an oral multitargeted receptor tyrosine kinase inhibitor, in patients with metastatic renal cell carcinoma Cancer Invest 29 2011 282 285
25. B.I. Rini, V. Shaw, J.E. Rosenberg Patients with metastatic renal cell carcinoma with long-term disease-free survival after treatment with sunitinib and resection of residual metastases Clin Genitourin Cancer 5 2006 232 234
26. M. Staehler, N. Haseke, E. Zilinberg Complete remission achieved with angiogenic therapy in metastatic renal cell carcinoma including surgical intervention Urol Oncol 28 2010 139 144
27. M. Johannsen, M. Staehler, C.H. Ohlmann Outcome of treatment discontinuation in patients with metastatic renal cell carcinoma and no evidence of disease following targeted therapy with or without metastasectomy Ann Oncol 22 2011 657 663
28. M.A. Vaz, V. Pachón, E. Grande Complete response to sunitinib in a patient with relapsed irresectable renal cell carcinoma Anticancer Drugs 22 2011 817 821
29. O.F. Calvo, D.D. Vázquez, M.R. López Renal cell carcinoma: complete response Anticancer Drugs 21 suppl 1 2010 S17 S18